![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Resistance monitoring data from treatment-naïve chronic HBV infected patients treated for 28
days with a new Class A core protein allosteric modulator RO7049389 monotherapy
|
|
|
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Xue Zhou1, Remi Kazma2, Dominik Matthias Meinel2, Yuan Zhou1, Junjun Cheng1, Man-Fung Yuen3, Edward Gane4, Christian Schwabe4, Tawesak Tanwandee5, Julian Zhou6, Qingyan Bo1
1 Roche Innovation Centre Shanghai, Shanghai, China; 2 Roche Innovation Centre Basel, Basel, Switzerland; 3 The University of Hong Kong, Hong Kong, China; 4 Auckland Clinical Studies, Auckland, New Zealand; 5 Mahidol University, Bangkok, Thailand; 6 Roche Products Limited, Shanghai, China
![0918201](../images/091820/091820-3/0918201.gif)
![0918202](../images/091820/091820-3/0918202.gif)
![0918203](../images/091820/091820-3/0918203.gif)
![0918204](../images/091820/091820-3/0918204.gif)
![0918205](../images/091820/091820-3/0918205.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|